PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26222F0024Plarify radioactive diagnostic AGENT — Progenics Pharmaceuticals, Inc

Progenics Pharmaceuticals, Inc holds $95.0M across 149 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36F79719D0170. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Oct 31, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22l (36C262)
Awarding office
Progenics Pharmaceuticals, Inc
Recipient
Oct 31, 2022
PoP end
$1.6M
Obligated
$2.5M
Potential
325412
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Progenics Pharmaceuticals, Inc — $90

Contract facts

Federal
Contract number36C26222F0024
Also listed as36C262-22-F-0024
Also listed as36F79719D0170-36C26222F0024
Agency262-Network Contract Office 22l (36C262)
Awarding office262-Network Contract Office 22l (36C262)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentProgenics Pharmaceuticals, Inc
CAGE34KE9
UEIYLYKVRPCTCR3
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79719D0170
Place of performanceNORTH BILLERICA MA
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startOct 1, 2021
PoP end (current)Oct 31, 2022
Obligated$1.6M
Current value$2.5M
Potential value$2.5M

PLARIFY RADIOACTIVE DIAGNOSTIC AGENT is a federal award for 262-Network Contract Office 22l (36C262) held by Progenics Pharmaceuticals, Inc. Estimated value $2.5M ($1.6M obligated). Current period of performance ends Oct 31, 2022. Last award drew 1 bidder. Place of performance: NORTH BILLERICA MA.

Recompete timing

Public
Past PoP end (1390 days ago)

Current PoP ended Oct 31, 2022 (1390 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Progenics Pharmaceuticals, Inc$95.0M obligated across 149 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($95.0M) · all agencies
Department of Veterans Affairs (VA)$93.8M · 99%Department of Health and Human Services (HHS)$1.1M · 1%Department of Defense (DOD)$105K · 0%
Open full company profile

Related awards

Same parent · incumbent
36C24625N1142
PYLARIFY F-18 INJECTIONS (336)
$1.2M
Aug 31, 2026
75N90025F00021
PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO.:1108959 [25-004297]
$611K
Sep 25, 2026
36C26126N0023
480 F18 PYLARIFY DOSES POP 1/1/2025 - 12/31/2025
$1.7M
Sep 26, 2026
75N90025F00003
PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO. [POTS 25-000073]
$2.1M
Sep 29, 2026
36C26122N0385
PYLARIFY (PIFLUFOLASTAT F18) NDC: 71258-0022-01
$4.5M
Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 36C26222F0024?

36C26222F0024 (Plarify radioactive diagnostic AGENT) is a 262-Network Contract Office 22l (36C262) award with a potential value of $2.5M, currently held by Progenics Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-22-F-0024?

36C262-22-F-0024 is the dashed form of PIID 36C26222F0024 (Plarify radioactive diagnostic AGENT), held by Progenics Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26222F0024?

262-Network Contract Office 22l (36C262) awarded 36C26222F0024 to Progenics Pharmaceuticals, Inc (potential $2.5M).

Who is the incumbent on 36C26222F0024?

Progenics Pharmaceuticals, Inc is the incumbent with $95.0M across 149 related awards in SCOUT’s public footprint. The current period of performance ends Oct 31, 2022.

When does Progenics Pharmaceuticals, Inc’s 36C26222F0024 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 31, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C26222F0024